NASDAQ: $NRXP Summary of the Article/Press Release On December 18, 2025, NRx Pharmaceuticals, Inc. (Nasdaq: $NRXP), a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders like suicidal depression and PTSD, announced that it has fully eliminated its balance sheet debt. CEO Dr. Jonathan Javitt thanked Anson Funds for their support during tough…